文献速递血脂与心血管预防

瑞卡西单抗作为他汀附加治疗非家族性高胆固醇血症:REMAIN-2随机3期试验

Recaticimab as Add-On Therapy to Statins for Nonfamilial Hypercholesterolemia: The Randomized, Phase 3 REMAIN-2 Trial.
PubMed 文献 · J Am Coll Cardiol · 2024-01-01

REMAIN-2为多中心随机双盲安慰剂对照3期试验,纳入689例非家族性高胆固醇血症患者,在他汀基础上加用瑞卡西单抗150mg每4周、300mg每8周或450mg每12周,24周LDL-C降幅显著优于安慰剂,并维持至48周,安全性良好。

要点

  • 瑞卡西单抗三种给药方案(Q4W、Q8W、Q12W)24周LDL-C降幅均显著优于安慰剂。
  • LDL-C降低效果维持至48周,最长给药间隔可达每12周一次。
  • 治疗相关不良事件发生率与安慰剂组相近,严重治疗相关不良事件率低。

核心结论

  • 在他汀稳定治疗基础上加用瑞卡西单抗可显著降低非家族性高胆固醇血症患者24周LDL-C水平,并维持至48周。
  • 瑞卡西单抗提供了一种给药间隔最长可达每12周一次的新型治疗选择。

研究设计与样本

  • REMAIN-2为多中心、随机、双盲、安慰剂对照3期试验。
  • 导入期患者接受稳定中等或高强度他汀(伴或不伴依折麦布或非诺贝特)≥4周。
  • LDL-C≥1.8 mmol/L(合并ASCVD)或≥2.6 mmol/L(无ASCVD)的患者按2:2:2:1:1:1随机接受瑞卡西单抗150mg Q4W、300mg Q8W、450mg Q12W或匹配安慰剂,治疗48周。
  • 共689例随机患者接受治疗,平均年龄55.8岁,男性64.4%,ASCVD史69.5%,合并依折麦布11.2%,平均基线LDL-C 2.8 mmol/L。

主要发现

  • 24周LDL-C自基线百分比变化瑞卡西单抗组显著优于安慰剂(P<0.0001)。
  • 最小二乘均值差异:150mg Q4W为-62.2%(95%CI:-67.0%至-57.4%),300mg Q8W为-59.7%(95%CI:-65.0%至-54.4%),450mg Q12W为-53.4%(95%CI:-58.7%至-48.2%)。
  • 瑞卡西单抗的LDL-C降低效果维持至48周。
  • 非高密度脂蛋白胆固醇、载脂蛋白B和脂蛋白(a)等次要血脂指标也倾向于瑞卡西单抗组。
  • 治疗期间治疗相关不良事件发生率(28.5% vs 26.6%)和严重治疗相关不良事件发生率(0.4% vs 0.4%)在瑞卡西单抗组与安慰剂组均较低且相近。

关键数值与推荐

  • 主要疗效终点为24周LDL-C自基线百分比变化。
  • 24周LDL-C降幅:150mg Q4W组较安慰剂组最小二乘均值差异-62.2%(95%CI:-67.0%至-57.4%)。
  • 24周LDL-C降幅:300mg Q8W组较安慰剂组最小二乘均值差异-59.7%(95%CI:-65.0%至-54.4%)。
  • 24周LDL-C降幅:450mg Q12W组较安慰剂组最小二乘均值差异-53.4%(95%CI:-58.7%至-48.2%)。

临床怎么用

  • 对于他汀治疗后LDL-C不达标的非家族性高胆固醇血症患者,可考虑加用瑞卡西单抗。
  • 瑞卡西单抗给药间隔最长可达每12周一次,可能提高长期治疗依从性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Currently available antiproprotein convertase subtilisin/kexin type 9 monoclonal antibodies can effectively decrease low-density lipoprotein cholesterol (LDL-C) levels, but require frequent dosing. Recaticimab is a novel humanized monoclonal antibody against proprotein convertase subtilisin/kexin type 9. In a phase 1b/2 trial, recaticimab as add-on to stable statins showed robust LDL-C reduction with a dosing interval up to every 12 weeks (Q12W) in patients with hypercholesterolemia. OBJECTIVES: REMAIN-2 (REcaticiMab Add-on therapy In patients with Nonfamilial hypercholesterolemia) aimed to assess the efficacy and safety of 48-week treatment with recaticimab as add-on therapy to statins in nonfamilial hypercholesterolemia. METHODS: REMAIN-2 was a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial. During the run-in period, patients received stable moderate or high-intensity statin, with or without cholesterol absorption inhibitors (ezetimibe) or fenofibrate, for ≥4 weeks. Patients with an LDL-C of ≥1.8 mmol/L (if with atherosclerotic cardiovascular disease [ASCVD]) or ≥2.6 mmol/L (if without ASCVD) were then randomized (2:2:2:1:1:1) to receive recaticimab 150 mg every 4 weeks (Q4W), 300 mg every 8 weeks (Q8W), or 450 mg Q12W, or matching placebo injections (Q4W, Q8W, or Q12W) for 48 weeks. The primary efficacy endpoint was percentage change from baseline to week 24 in LDL-C level. RESULTS: A total of 689 randomly assigned patients received treatment (mean age, 55.8 years; male, 64.4%; ASCVD history, 69.5%; concomitant ezetimibe, 11.2%; mean baseline LDL-C, 2.8 mmol/L). Percentage change in LDL-C from baseline to week 24 was significantly more pronounced with recaticimab vs placebo (P < 0.0001), with least-squares mean differences of -62.2% (95% CI: -67.0% to -57.4%), -59.7% (95% CI: -65.0% to -54.4%), and -53.4% (95% CI: -58.7% to -48.2%) for the 150 mg Q4W, 300 mg Q8W, and 450 mg Q12W regimens, respectively. The decreases in LDL-C with recaticimab were maintained through week 48. Secondary lipid variables, including non-high-density lipoprotein cholesterol, apolipoprotein B, and lipoprotein(a) also favored the recaticimab groups. During the treatment period, the incidence of treatment-related adverse events (28.5% vs 26.6%) and serious treatment-related adverse events (0.4% vs 0.4%) was similarly low in both the recaticimab and placebo groups. CONCLUSIONS: Recaticimab as add-on to stable statin therapy significantly decreased LDL-C levels at week 24 and sustained the decreases through week 48, providing a novel therapeutic alternative with a dosing interval of up to every 12 weeks in patients with nonfamilial hypercholesterolemia.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Sun Y, Lv Q, Guo Y, et al. Recaticimab as Add-On Therapy to Statins for Nonfamilial Hypercholesterolemia: The Randomized, Phase 3 REMAIN-2 Trial. J Am Coll Cardiol. 2024. PMID: 39505412. doi:10.1016/j.jacc.2024.09.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。